2022 Brings the Latest in Testing and Treatments for Alzheimer’s Disease
Testing for Earlier Diagnosis
In May 2022, Fujirebio Diagnostic developed a new testing application for patients 55 years and older who have shown cognitive impairment. The test was able to get through an expedited review process. It can be used to detect brain plaques and analyze spinal fluid and proteins that accumulate to form the amyloid-beta plaques tied to Alzheimer’s disease. The FDA suggests testing be combined with other clinical evaluations to confirm a diagnosis.
Doctors and medical labs evaluate the future of alzheimer's
A survey by the Harris Poll for Quest Diagnostics suggests half of physicians don’t think Alzheimer’s will ever be cured, but about 75% thought new therapies might help manage the disease. Quest introduced a blood test in March for the early detection of Alzheimer’s. The company wants to see physicians and patients begin to prepare for the newer, more convenient diagnostics to become widespread tools in the health care industry. Diagnostic blood tests would be faster and more cost-effective for the healthcare system overall and lead to a more immediate referral to specialists. However, the majority of clinicians also feared the blood tests for Alzheimer’s would cause a surge in diagnoses and stress the health care system.
What next?
- Give us a call at 720-821-7604 to schedule a "Discovery Session" at which we can determine whether our firm would be a good fit for your needs. Or fill out our contact form to have us call you.
- Visit our estate planning page to learn more about how proactively thinking through your estate plan can protect you and your family, minimize hassle, lower the chance of family discord, and minimize or eliminate taxes.
- Learn more by reading our blog or watching our videos .
